GILEAD SCIENCES, INC. is 57.2x more valuable than Tarsus Pharmaceuticals, Inc. by market capitalization ($150.83 B vs $2.64 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | TARS | GILD |
|---|---|---|
| Market cap | $2.64 B | $150.83 B |
| US-listed rank | #1904 | #99 |
| Revenue (latest FY) | $451.36M | $29.44B |
| Net income (latest FY) | -$66.00M | $8.51B |
| Net margin | -14.6% | 28.9% |
| P/E (trailing FY) | - | 17.7 |
| SEC filings | 617 | 981 |
GILEAD SCIENCES, INC. is 57.2x more valuable than Tarsus Pharmaceuticals, Inc. by market capitalization ($150.83 B vs $2.64 B).
In their latest fiscal years, Tarsus Pharmaceuticals, Inc. reported $451.36M in revenue while GILEAD SCIENCES, INC. reported $29.44B.
Full pages: Tarsus Pharmaceuticals, Inc. and GILEAD SCIENCES, INC., or browse the full rankings.